The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Pathological growth of cardiomyocytes (hypertrophy) is a major determinant for the development of heart failure, one of the leading medical causes of mortality worldwide. Here we show that the microRNA (miRNA)-212/132 family regulates cardiac hypertrophy and autophagy in cardiomyocytes. Hypertrophic stimuli upregulate cardiomyocyte expression of miR-212 and miR-132, which are both necessary and sufficient to drive the hypertrophic growth of cardiomyocytes. MiR-212/132 null mice are protected from pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to pathological cardiac hypertrophy, heart failure and death in mice. Both miR-212 and miR-132 directly target the anti-hypertrophic and pro-autophagic FoxO3 transcription factor and overexpression of these miRNAs leads to hyperactivation of pro-hypertrophic calcineurin/NFAT signalling and an impaired autophagic response upon starvation. Pharmacological inhibition of miR-132 by antagomir injection rescues cardiac hypertrophy and heart failure in mice, offering a possible therapeutic approach for cardiac failure. Heart failure is often a consequence of pathological growth of cardiomyocytes or cardiac hypertrophy. Here Ucar and colleagues report that the microRNAs miR-132 and miR-212 promote cardiac hypertrophy and inhibit autophagy in cardiomyocytes by downregulating the transcription factor FoxO3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, fine-tuning of FOXO3 levels has been achieved via a miRNA-132 antagonistic approach,157 that is currently clinically tested (NCT04045405).”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [157]
In the citing paper
“| Cardiomyopathies | Cardiomyocyte‐specific overexpression of miR‐212/132 | Pathological cardiac hypertrophy, heart failure, and premature death, after impaired autophagic response upon starvation | Ucar et al (2012) |”
From Autophagy in major human diseases (2021) · cites this paper as Ucar et al (2012)
In the citing paper
“Along similar lines, the cardiomyocyte‐specific overexpression of miRNAs invalidating the transcriptional activity of FOXO3 (Ucar et al, 2012) or activating MTORC1 (Li et al, 2017) precipitates cardiac function, leading to heart failure.”
From Autophagy in major human diseases (2021) · cites this paper as Ucar et al, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Self-citationHomeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice.
Komatsu, M., Waguri, S., Koike, M., Sou, Y.-S., Ueno, T., Hara, T., Mizushima, N., Iwata, J.-I., Ezaki, J., Murata, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.035 · Cited by 2,124
Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
Control of translation and mRNA degradation by miRNAs and siRNAs: Table 1.
Valencia-Sanchez, M. A., Liu, J., Hannon, G. J., & Parker, R. (2006) · Genes & Development · doi:10.1101/gad.1399806 · Cited by 2,060
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Ventura, A., Young, A. G., Winslow, M. M., Lintault, L., Meissner, A., Erkeland, S. J., Newman, J., Bronson, R. T., Crowley, D., Stone, J. R., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.019 · Cited by 1,590
Cited by
Items 301–400 of 609
Novel aberrant genetic and epigenetic events in Friedreich׳s ataxia
Quesada, M. P., Jones, J., Rodríguez‐Lozano, F. J., Moraleda, J. M., & Martı́nez, S. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.04.013 · Cited by 23
“cardiomyocytes, as miR-132 expression is upregulated in cardiomyocytes during hypertrophy both in vitro and in vivo in rats, and miR-132 is necessary and sufficient for cardiomyocyte hypertrophy in vitro [46].”
BackgroundNoncoding RNAs regulating cardiac muscle mass
Wadley, G. D., Lamon, S., Alexander, S. E., McMullen, J. R., & Bernardo, B. C. (2018) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00904.2018 · Cited by 23
“The miR-212/-132 family has been implicated in pathological cardiac hypertrophy (40) and cardiomyocyte autophagy (118) and is regulated by angiotensin-II (ANG II) (40), a peptide hormone playing an important role in cardiovascular disease (82).”
BackgroundBen‐Nun, D., Buja, L. M., & Fuentes, F. J. (2020) · Cardiovascular Pathology · doi:10.1016/j.carpath.2020.107243 · Cited by 28
Dimitrakopoulou, K., Vrahatis, A. G., & Bezerianos, A. (2015) · BMC Genomics · doi:10.1186/s12864-015-1256-3 · Cited by 24
“miR-132 miR-190b 221 Various diseases [32]”
BackgroundTu, Y., Wan, L., Zhao, D., Bu, L., Dong, D., Yin, Z., Cheng, Z., & Shen, B. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2596-3 · Cited by 24
Senger, N., Parletta, A. C., Marques, B. V. D., Akamine, E. H., Diniz, G. P., Campagnole‐Santos, M. J., Santos, R. A. S., & Barreto‐Chaves, M. L. M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30069 · Cited by 21
“decompensated cardiac hypertrophy, heart failure, and death in mice (Ucar et al., 2012).”
BackgroundChen, Q., Jiang, Y.-N., Guan, X., Ren, F., Wu, S., Chu, M., Wu, L., Lai, T.-F., & Li, L. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010569 · Cited by 33
MiR-9 enhances the sensitivity of A549 cells to cisplatin by inhibiting autophagy
Zhang, Y., Meng, X., Li, C., Tan, Z., Guo, X., Zhang, Z., & Xi, T. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2325-2 · Cited by 22
Cellular Protein Quality Control in Diabetic Cardiomyopathy: From Bench to Bedside
Kaur, N., Raja, R., Ruiz‐Velasco, A., & Liu, W. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.585309 · Cited by 24
“Mir212 targets Foxo3a (329), while mir221 targets p27 mRNA, modulating MTORC1 activity (330), both of which inhibit autophagy.”
BackgroundEpigenetic regulation in cardiac fibrosis
Yu, L., & Xu, Y. (2015) · World Journal of Cardiology · doi:10.4330/wjc.v7.i11.784 · Cited by 22
Kaneko, M., Satomi, T., Fujiwara, S., Uchiyama, H., Kusumoto, K., & Nishimoto, T. (2016) · Biomarkers · doi:10.1080/1354750x.2016.1204001 · Cited by 25
“Genetic deletion or overexpression of miRNAs in mice affects the progression of heart failure (Li et al., 2013; Ucar et al., 2012).”
BackgroundYin, G., Yang, X., Li, Q., & Guo, Z. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26623 · Cited by 22
“For example, overexpression of the miR-212/132 family lead to pathological cardiac hypertrophy, heart failure and autophagic cell death in mice.(11) MiR-204 post-transcriptionally suppressed the expression of LC3-II and inhibited cardiomyocyte autophagy under ischemia-hypoxia condition.”
BackgroundROS-mediated bidirectional regulation of miRNA results in distinct pathologic heart conditions
Lee, S., Lim, S., Ham, O., Lee, S.-Y., Lee, C. Y., Park, J., Lee, J., Seo, H., Yun, I., Han, S. M., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.160 · Cited by 21
Roles of microRNAs in pressure overload- and ischemia-related myocardial remodeling
Zhou, S., Liu, Y., Prater, K., Zheng, Y., & Cai, L. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.08.023 · Cited by 22
MicroRNAs in platelet physiology and pathology
Dangwal, S., & Thum, T. (2013) · Hämostaseologie · doi:10.5482/hamo-13-01-0002 · Cited by 21
Self-citationFeedback Mechanisms for Cardiac-Specific MicroRNAs and cAMP Signaling in Electrical Remodeling
Myers, R., Timofeyev, V., Li, N., Kim, C., Ledford, H. A., Sirish, P., Lau, V. C., Zhang, Y., Fayyaz, K., Singapuri, A., et al. (2015) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.114.002162 · Cited by 21
Noncoding RNAs: potential regulators in cardioncology
Chatterjee, S., Gupta, S. K., Bär, C., & Thum, T. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00418.2018 · Cited by 21
Self-citationMicroRNAs and therapeutic potentials in acute and chronic cardiac disease
Song, R., & Zhang, L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104179 · Cited by 23
Deng, H., He, Z.-Y., Dong, Z., Zhang, Y., Han, X., & Li, H. (2021) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-021-00861-6 · Cited by 20
Salvatori, F., D’Aversa, E., Serino, M. L., Singh, A. V., Secchiero, P., Zauli, G., Tisato, V., & Gemmati, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713268 · Cited by 23
Qian, L.-B., Jiang, S., Tang, X., Zhang, J., Liang, Y., Yu, H., Chen, J., Xu, Z., Liu, R.-M., Keller, B. B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21302 · Cited by 21
RNA therapeutics for heart disease
Majo, F. D., & Windt, L. J. D. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.037 · Cited by 21
Fang, X., Miao, S., You, Y., Ding, F., Han, X., Wu, H., Zhao, Z., Wang, Y., Hu, S., & Lei, W. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.06.014 · Cited by 20
Ban, E., Kwon, H., Seo, H. S., Yoo, Y. S., & Song, E. J. (2021) · BMC Biotechnology · doi:10.1186/s12896-021-00710-w · Cited by 21
“In the AMI group, mean miRNA-132 levels were lower than those in the control group, consistent with previous results [19]; however, the difference was small and observed individual difference.”
ResultMicroRNA and Heart Failure: A Novel Promising Diagnostic and Therapeutic Tool
D’Amato, A., Prosperi, S., Severino, P., Myftari, V., Correale, M., Filardi, P. P., Badagliacca, R., Fedele, F., Vizza, C. D., & Palazzuoli, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247560 · Cited by 24
An Overview of miRNAs Involved in PASMC Phenotypic Switching in Pulmonary Hypertension
Zhang, W., Tao, Z., Xu, F., Diao, Q., Li, J., Zhou, L., Miao, Y., Xie, S., Wan, J., & Xu, R. (2021) · BioMed Research International · doi:10.1155/2021/5765029 · Cited by 20
Zhang, C. J., Huang, Y., Lu, J., Lin, J., Ge, Z., & Huang, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27081 · Cited by 21
“Interestingly, overexpression of the miR‐212/132 family was also proven to result in pathological cardiac hypertrophy and heart failure.(34) Masson et al(35) observed that higher circulating levels of miR‐132 were independently related to higher diastolic blood pressure, ischemic etiology of heart failure, higher chol…”
BackgroundRetractedEpigenetic Regulation of Autophagy in Cardiovascular Pathobiology
Bu, S., & Singh, K. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126544 · Cited by 19
Luo, F., Liu, W., & Bu, H. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10231-z · Cited by 17
Rana, I., Velkoska, E., Patel, S. K., Burrell, L. M., & Charchar, F. J. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00183.2015 · Cited by 19
MicroRNAs with Mega Functions in Cardiac Remodeling and Repair
Haider, K. H., Khan, M., & Sen, C. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405544-5.00022-8 · Cited by 18
Noncoding RNAs in exercise-induced cardio-protection for chronic heart failure
Ma, S., & Liao, Y. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.051 · Cited by 19
“antihypertrophic and proautophagic factor, while antagomir-mediated knockdownofmiR-132weakened this effect and alleviated theprogression to CHF [31].”
BackgroundYang, M., Song, J., Yang, X., Zhong, G., & Zhong, J. (2022) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-022-00651-4 · Cited by 19
Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
Chen, Y., Zhou, J., Wei, Z., Cheng, Y., Tian, G., Quan, Y., Kong, Q., Wu, W., & Liu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.940768 · Cited by 17
“, 2006) and participate in various physiological processes of the cardiovascular system, such as proliferation, differentiation, oxidative stress, autophagy and apoptosis (Xu et al., 2004; Cheng et al., 2005; Ucar et al., 2012).”
BackgroundNanocarriers for gene delivery to the cardiovascular system
Shi, L.-X., Liu, X.-R., Zhou, L.-Y., Zhu, Z., Yuan, Q., & Zou, T. (2023) · Biomaterials Science · doi:10.1039/d3bm01275a · Cited by 20
Abu‐Halima, M., Poryo, M., Ludwig, N., Mark, J., Marsollek, I., Giebels, C., Petersen, J., Schäfers, H., Grundmann, U., Pickardt, T., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1213-9 · Cited by 21
“Its up-regulation expression leads to pathological cardiac hypertrophy [47].”
BackgroundA new miRNA regulator, miR-672, reduces cardiac hypertrophy by inhibiting JUN expression
Lu, Y., & Wu, F. (2018) · Gene · doi:10.1016/j.gene.2018.01.047 · Cited by 20
Harnessing the Therapeutic Potential of MicroRNAs for Cardiovascular Disease
Calway, T., & Kim, G. H. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414552902 · Cited by 17
“Similarly, miR-132 inhibition was found to suppress calcineurin and NFAT signaling after pressure overload and attenuate the development of hypertrophy.(69)”
BackgroundGenetic background-dependent effects of murine micro RNAs on circadian clock function
Kießling, S., Uçar, A., Chowdhury, K., Oster, H., & Gregor Eichele, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176547 · Cited by 17
Self-citationLncRNAs: Proverbial Genomic “Junk” or Key Epigenetic Regulators During Cardiac Fibrosis in Diabetes?
Biswas, S., Thomas, A. A., & Chakrabarti, S. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00028 · Cited by 18
Li, Y., Zhang, X., Fu, Z., & Zhou, Q. (2019) · Current Neurovascular Research · doi:10.2174/1567202616666191111104145 · Cited by 17
MicroRNAs in cardiovascular diseases
Li, H., Zhan, J., Chen, C., & Wang, D. W. (2022) · Medical Review · doi:10.1515/mr-2021-0001 · Cited by 19
Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
Jalink, E. A., Schonk, A. W., Boon, R. A., & Juni, R. P. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1300375 · Cited by 18
Exploring the role of pericardial miRNAs and exosomes in modulating cardiac fibrosis
Schoettler, F. I., Hassanabad, A. F., Jadli, A. S., Patel, V. B., & Fedak, P. W. M. (2024) · Cardiovascular Pathology · doi:10.1016/j.carpath.2024.107671 · Cited by 18
Molecular Basis of Cardiomyopathies in Type 2 Diabetes
Giardinelli, S., Meliota, G., Mentino, D., D’Amato, G., & Faienza, M. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158280 · Cited by 18
“In animal models, the suppression of overexpressed miRNA in heart failure was studied with promising results [165].”
BackgroundLeveraging metabolism for better outcomes in heart failure
Ng, Y. H., Koay, Y. C., Marques, F. Z., Kaye, D. M., & O’Sullivan, J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae216 · Cited by 20
Kattih, B., Fischer, A., Muhly-Reinholz, M., Tombor, L., Nicin, L., Cremer, S., Zeiher, A. M., John, D., Abplanalp, W. T., & Dimmeler, S. (2024) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2024.11.004 · Cited by 17
Gohir, W., Klement, W., Singer, L. G., Palmer, S. M., Mazzulli, T., Keshavjee, S. H., & Husain, S. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.07.014 · Cited by 16
Eikelis, N., Dixon, J. B., Lambert, É., Hanin, G., Tzur, Y., Greenberg, D., Soreq, H., Marques, F. Z., Fahey, M. T., Head, G. A., et al. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00597-2 · Cited by 16
Xu, Q., Liang, Y., Liu, X., Zhang, C., Liu, X., Li, H., Liang, J., Yang, G., & Ge, Z. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10380 · Cited by 20
“it has been reported that mir-132 is involved in diabetic complications and cVds, including diabetic cardiac microangiopathy, neointimal hyperplasia, cardiac hypertrophy endothelial cell function and angiogenesis (34-36).”
BackgroundWang, J., Liu, Y., Yan, Y., Wang, A., Jiang, Y.-Y., Wen, Z.-X., Qiao, K., Li, H., Hu, T.-T., Ma, Y., et al. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.135213 · Cited by 16
Emerging Technologies and Future Directions in Interorgan Crosstalk Cardiometabolic Research
Bae, H., Nguyen, C. M., Ruiz‐Orera, J., Mills, N. L., Snyder, M. P., Jang, C., Shah, S. H., Hübner, N., & Seldin, M. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325515 · Cited by 16
Therapeutic potentials of modulating autophagy in pathological cardiac hypertrophy.
Shi, S., & Jiang, P. (2022) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2022.113967 · Cited by 14
Li, T., Yu, S., Zhou, C., Wang, K., & Wan, Y. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1616744 · Cited by 15
“Considering many potential targets governed by each miRNA, one challenge in understanding functional miRNA’s contributions to autophagy of cardiomyocytes depends on the identification of these targets [22].”
BackgroundRetractedMiR-590-5p inhibits pathological hypertrophy mediated heart failure by targeting RTN4
Fan, P., Zhang, L., Cheng, T., Wang, J., Zhou, J., Zhao, L., Hua, C., & Xia, Q. (2021) · Journal of Molecular Histology · doi:10.1007/s10735-021-10009-x · Cited by 15
Micro RNA s in Bladder Outlet Obstruction: Relationship to Growth and Matrix Remodelling
Ekman, M., Albinsson, S., Uvelius, B., & Swärd, K. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12534 · Cited by 18
“In the heart they are involved in the development of hypertrophy [55], and in leucocytes they repress acetylcholine esterase, Ache [56].”
BackgroundBladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor
Kashyap, M. P., Pore, S. K., Chancellor, M. B., Yoshimura, N., & Tyagi, P. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.10.025 · Cited by 16
“FOXO3 is also known to be involved in cardiac hypertrophy (Ucar et al., 2012) and may also explain the miR-132 mediated bladder hypertrophy.”
BackgroundBauersachs, J. K., Solomon, S. D., Anker, S. D., Antorrena, I., de Boer, R. A., Filippatos, G. S., Friede, T., Hauke, W., Ponikowski, P. P., Vardeny, O., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04408-4 · Cited by 14
“Among these, miR-132 is upregulated in response to myocardial stress and functions as a nodal driver of adverse remodeling 4,5 .”
Self-citationThe role of microRNAs in the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy
Rhman, M. A., & Owira, P. M. O. (2022) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgac066 · Cited by 14
Autophagy in spinal muscular atrophy: from pathogenic mechanisms to therapeutic approaches
Rashid, S., & Dimitriadi, M. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1307636 · Cited by 18
Teng, L., Huang, Y., Guo, J., Li, B., Jin, L., Ma, L., Wang, Y., Ye, C., & Chen, Q. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15814 · Cited by 15
MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review
Chen, L., & Xu, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.740515 · Cited by 17
Non-coding RNAs and Pathological Cardiac Hypertrophy
He, J., Luo, Y., Song, J., Tan, T., & Zhu, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1671-9_13 · Cited by 13
Non-Coding RNA Databases in Cardiovascular Research
Balamurali, D., & Stoll, M. (2020) · Non-Coding RNA · doi:10.3390/ncrna6030035 · Cited by 14
“miR-132 has been extensively studied as a putative therapeutic biomarker, due to its role in cardiac hypertrophy and heart failure, through its effect on the pro-hypertrophic calcineurin/NFAT pathway [28,29].”
BackgroundCircular RNAs in the regulation of cardiac hypertrophy
Wu, S., Chen, L., & Zhou, X. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.12.025 · Cited by 16
“In support of this hypothesis, they showed that custom-built circRNA sponges (circmiRs) targeting miR-132 and miR-212 were able to drive the hypertrophic growth of cardiomyocytes.(59) circmiRs containing 12 miRNA binding sites were found to be optimal, and, when delivered to cardiomyocytes in vivo using AAV9 vectors,…”
BackgroundOxidative Stress, Mitochondrial Quality Control, Autophagy, and Sirtuins in Heart Failure
Krekora, J., Derwich, M., Dróżdż, J., Pawłowska, E., & Błasiak, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199826 · Cited by 18
“In another epigenetic-related study, it was observed that the miRNA-212/132 family influenced cardiac hypertrophy and autophagy in cardiomyocytes [133].”
Zhang, F., Gao, F., Wang, K., Liu, X., & Zhang, Z. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02183-2 · Cited by 13
RetractedLong non-coding RNAs in cardiac hypertrophy
Sun, J., & Wang, C. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09882-2 · Cited by 15
Wu, P., Chen, L., Cheng, J. R., Pan, Y., Zhu, X., Bao, L., Chu, W., & Zhang, J. (2021) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2021.111003 · Cited by 13
Saini, V. M., Liu, K. R., Surve, A. S., Gupta, S., & Gupta, A. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01066-4 · Cited by 16
Self-citationNon-coding RNAs: Important participants in cardiac fibrosis
Dong, Y., Peng, N., Dong, L., Tan, S., & Zhang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.937995 · Cited by 15
“Inhibition of Foxo3 by miR-212/132 leads to downregulation of autophagy level and upregulation of calcineurin/NFAT signaling, as well as deterioration of cardiac function (29).”
BackgroundInfluentialmiRNAs in Uremic Cardiomyopathy: A Comprehensive Review
D’Agostino, M., Mauro, D., Zicarelli, M., Carullo, N., Greco, M., Andreucci, M., Coppolino, G., & Bolignano, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065425 · Cited by 12
“In these animals, AKI was followed by an increase in miR-212 and miR-132 expression, two miRNAs which are well acknowledged for their pro-fibrotic effect based on the suppression of the antihypertrophic FoxO3 target gene [49].”
BackgroundMicroRNAs-associated with FOXO3 in cellular senescence and other stress responses
Khor, Y.-S., & Wong, P. (2023) · Biogerontology · doi:10.1007/s10522-023-10059-6 · Cited by 16
Shimizu, T., Taguchi, A., Higashijima, Y., Takubo, N., Kanki, Y., Urade, Y., & Wada, Y. (2020) · iScience · doi:10.1016/j.isci.2020.101410 · Cited by 13
Schimmel, K., Stojanović, S. D., Huang, C.-K., Jung, M., Meyer, M. H. F., Xiao, K., Grote-Levi, L. M., Bär, C., Pfanne, A., Mitzka, S., et al. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.10.008 · Cited by 13
Self-citationMitochondrial microRNAs: A Putative Role in Tissue Regeneration
Rodrigues, S. C., Cardoso, R. M. S., & Duarte, F. V. (2020) · Biology · doi:10.3390/biology9120486 · Cited by 14
“Also, miR-212/132 family [112] and miR-23a [113] target Foxo3 transcription factor in cardiomyocytes, which alleviates the hypertrophic clues, while miR-29a-3p hinders ET-1-induced hypertrophic response in cardiomyocytes by directly targeting 3′ UTR of NFATc4 [114].”
BackgroundMicroRNA-based therapy in cardiology
Fiedler, J., Bátkai, S., & Thum, T. (2014) · Herz · doi:10.1007/s00059-013-4047-0 · Cited by 14
Self-citationMethods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics
Afrin, H., Salazar, C. J. J., Kazi, M., Ahamad, S. R., Alharbi, M., & Nurunnabi, M. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.01.011 · Cited by 13
Angeli, E., Jordan, M., Otto, M., Stojanović, S. D., Karsdal, M. A., Bauersachs, J. K., Thum, T., Fiedler, J., & Genovese, F. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.02.008 · Cited by 15
Self-citationThe Role of MicroRNAs in the Pathogenesis of Doxorubicin-Induced Vascular Remodeling
Podyacheva, E., Snezhkova, J., Onopchenko, A., Dyachuk, V. A., & Toropova, Y. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413335 · Cited by 12
“Several studies [113,134] have demonstrated the role of the miR-212/132 family in the development of myocardial hypertrophy and autophagy processes.”
MicroRNA and receptor mediated signaling pathways as potential therapeutic targets in heart failure
Tuttolomondo, A., Simonetta, I., & Pinto, A. V. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1212017 · Cited by 12
Comprehensive Bioinformatics Identifies Key microRNA Players in ATG7-Deficient Lung Fibroblasts
Stojanović, S. D., Fuchs, M., Fiedler, J., Xiao, K., Meinecke, A., Just, A., Pich, A., Thum, T., & Kunz, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114126 · Cited by 13
“Autophagy processes are actively regulated at the post-transcriptional level through microRNA (miR) [18].”
BackgroundSelf-citationMuscle Regeneration and RNA: New Perspectives for Ancient Molecules
Buonaiuto, G., Desideri, F., Taliani, V., & Ballarino, M. (2021) · Cells · doi:10.3390/cells10102512 · Cited by 12
“Specifically, Lavenniah and colleagues designed synthetic circ-miR sponges against miR-132 and miR-212, both involved in pathological hypertrophy [104].”
BackgroundAn Overview of Non-coding RNAs and Cardiovascular System
Mushtaq, I., Ishtiaq, A., Ali, T., Jan, M. I., & Murtaza, I. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1671-9_1 · Cited by 14
Zinc-finger protein 418 overexpression protects against cardiac hypertrophy and fibrosis
Pan, L., Sheng, M., Huang, Z., Zhu, Z., Xu, C., Teng, L., He, L., Gu, C. J., Cai, Y., & Li, J.-M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186635 · Cited by 12
Shaharyar, M. A., Bhowmik, R., Al-Abbasi, F. A., AlGhamdi, S. A., Alghamdi, A. M., Sarkar, A., Kazmi, I. A., & Karmakar, S. (2023) · Vaccines · doi:10.3390/vaccines11020241 · Cited by 12
“Eventually, miR-212/132 antagonism reverses TAC-induced ventricular hypertrophy and failing heart in mice [50,51].”
Hu, C., Zhao, X., Cui, C., Zhang, Y., Zhu, Q., Yin, H., & Han, S. (2023) · Theriogenology · doi:10.1016/j.theriogenology.2023.10.024 · Cited by 13
Mohammed, O. A., Alghamdi, M. A. A., Alfaifi, J. A., Alamri, M. M. S., Alshahrani, A. M., Alharthi, M. H., Alshahrani, A. M., Alhalafi, A. H., Adam, M. I. E., Bahashwan, E., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.155087 · Cited by 11
Non-coding RNAs and angiogenesis in cardiovascular diseases: a comprehensive review
Zhang, J. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04919-5 · Cited by 13
“In heart failure models caused by hypertension, Additionally, it is claimed that they are increased in failing human hearts, where they adversely affect the cardiomyocyte contractility’s regulation along with cardiac hypertrophy [70].”
The multifaceted role of autophagy and mitophagy in cardiovascular health and disease
Nàger, M., Calvoli, M., Larsen, K. B., & Birgisdottir, Å. B. (2025) · Autophagy Reports · doi:10.1080/27694127.2025.2572511 · Cited by 13
“Mice deficient of miR-212 and miR-132 display induced autophagy and are protected from PO-induced HF [96] .”
Panera, N., Gnani, D., Piermarini, E., Petrini, S., Bertini, E., Nobili, V., Pastore, A., Piemonte, F., & Alisi, A. (2016) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2016.01.001 · Cited by 11
Autophagy in cardiac metabolic control: Novel mechanisms for cardiovascular disorders
Yang, Y., Zhao, C., Yang, P., Wang, X., Wang, L., & Chen, A. (2016) · Cell Biology International · doi:10.1002/cbin.10626 · Cited by 12
“The AMPK (adenosine monophosphate activated protein kinase)mTOR pathway activates autophagy, which is considered to be adaptive during mild ischemic stress, as inhibited autophagic activity enhances cardiomyocyte death (Valentim et al., 2006).”
BackgroundNon-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy
Silva, J., & Martins, P. A. D. C. (2022) · Cells · doi:10.3390/cells11111805 · Cited by 12
“miR-212/132 can, also, regulate the FoxO3/calcineurin/NFAT pathway, with their overexpression inducing pathological cardiac hypertrophy in mice, by hyper activating calcineurin/NFAT signaling [61].”
BackgroundFacts and Updates About Cardiovascular Non-Coding Rnas in Heart Failure
Thum, T. (2015) · ESC Heart Failure · doi:10.1002/ehf2.12054 · Cited by 13
“of miR-132 rescued cardiac hypertrophy and HF in mice, suggesting a novel therapeutic approach for this pathology.(10) REV IEW”
BackgroundSelf-citationSugemule-3 protects against isoprenaline-induced cardiotoxicity In vitro
Yu, L.-J., Wei, C., Wang, Y., Gong, G.-H., & Xu, Y. (2017) · Pharmacognosy Magazine · doi:10.4103/0973-1296.211018 · Cited by 11
Chodkowska, K. A., Ciecierska, A., Majchrzak, K., Ostaszewski, P., & Sadkowski, T. (2018) · Nutrients · doi:10.3390/nu10121871 · Cited by 11
“Other identified miRNAs, miR-199, miR-142-3p, and miR-212, play important roles in different kinds of cardiac hypertrophy [42].”
BackgroundQian, L., Pan, S., Shi, L., Zhou, Y., Sun, L., Wan, Z., Ding, Y., & Qian, J. (2019) · Aging · doi:10.18632/aging.102112 · Cited by 11
RetractedNon-coding RNA therapeutics in the treatment of heart failure
Paterek, A., Załęska‐Kocięcka, M., Surzykiewicz, M., Wojdyńska, Z., Leszek, P., & Ma̧czewski, M. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae027 · Cited by 10
Cardiovascular Disease and miRNAs: Possible Oxidative Stress-Regulating Roles of miRNAs
Lee, S. (2024) · Antioxidants · doi:10.3390/antiox13060656 · Cited by 16
“Furthermore, its up-regulation has been reported in mice with TAC-induced cardiac hypertrophy [261,262].”
BackgroundInvestigating microRNAs in diabetic cardiomyopathy as tools for early detection and therapeutics
Mathur, P., & Rani, V. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04473-6 · Cited by 10
Metadata
- Authors
- Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., Dangwal, S., Kumarswamy, R., Bang, C., Holzmann, A., Remke, J., Caprio, M., Jentzsch, C., Engelhardt, S., Geisendorf, S., Glas, C., Hofmann, T. G., Nessling, M., Richter, K., Schiffer, M., Carrier, L., Napp, L. C., Bauersachs, J., Chowdhury, K., & Thum, T.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- IRCCS San Raffaele Roma (IT)
- Technical University of Munich (DE)
- Max Planck Institute for Biophysical Chemistry (DE)
- German Cancer Research Center (DE)
- Mount Desert Island Biological Laboratory (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Corresponding author
- Chowdhury, Kamal
- Thum, Thomas
- ORCID
- Venue
- Nature Communications
- Published
- 2012-09-25
- Volume
- 3
- Issue
- 1
- Pages
- 1078-1078
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3657998
- OpenAlex
- W2101080348
- Cited by
- 610
- References
- 46
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 47 · 2023: 32 · 2022: 60 · 2021: 53 · 2020: 52 · 2019: 41 · 2018: 43 · 2017: 51 · 2016: 47 · 2015: 67 · 2014: 44 · 2013: 26
- FWCI
- 28.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Baden-Württemberg Stiftung
- Deutsches Krebsforschungszentrum
- Deutsche Forschungsgemeinschaft (DFG-TH903/10-1, 01EO0802, SCHI587/3)
- Bundesministerium für Bildung und Forschung (01EO0802)
- Max-Planck-Gesellschaft
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- miR-212, miR-132, cardiac hypertrophy, cardiomyocyte autophagy, heart failure, FOXO3, pressure overload, antagomir, cardiomyocyte-specific overexpression, starvation-induced autophagy
- MeSH terms
- Antagomirs, Animals, Autophagy, Cells, Cultured, Cardiomegaly, Male, Mice, Transgenic, Oligonucleotides, Calcineurin, Reverse Transcriptase Polymerase Chain Reaction, Myocytes, Cardiac, MicroRNAs, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.